Understanding how mis-splicing affects cancer characteristics
Dissecting the contribution of mis-splicing in cancer phenotypes through multi-omic single-cell approaches
['FUNDING_CAREER'] · WEILL MEDICAL COLL OF CORNELL UNIV · NIH-11035949
This study is looking at how mistakes in the way RNA is processed can affect cancer cells and their behavior, with the hope of finding new ways to improve treatments for patients with cancers like myelodysplastic syndromes and ovarian cancer.
Quick facts
| Phase | ['FUNDING_CAREER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | WEILL MEDICAL COLL OF CORNELL UNIV (nih funded) |
| Locations | 1 site (NEW YORK, UNITED STATES) |
| Trial ID | NIH-11035949 on ClinicalTrials.gov |
What this research studies
This research investigates how errors in RNA splicing contribute to the diversity of cancer cells and their behaviors. By examining specific mutations in splicing factors across different cancer types, including myelodysplastic syndromes and ovarian cancer, the study aims to uncover how these splicing errors influence tumor development and immune responses. The research employs advanced techniques like single-cell sequencing to analyze individual cancer cells, providing insights into their unique characteristics and potential vulnerabilities. Ultimately, the goal is to identify new targets for immunotherapy that could improve treatment outcomes for patients.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with myelodysplastic syndromes or high-grade serous ovarian cancer.
Not a fit: Patients with cancers not related to splicing errors or those without the specific mutations being studied may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new immunotherapy strategies that specifically target cancer cells based on their unique splicing profiles.
How similar studies have performed: Similar research has shown promise in understanding the role of splicing in cancer, suggesting that this approach could yield valuable insights.
Where this research is happening
NEW YORK, UNITED STATES
- WEILL MEDICAL COLL OF CORNELL UNIV — NEW YORK, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: CORTES LOPEZ, MARIELA — WEILL MEDICAL COLL OF CORNELL UNIV
- Study coordinator: CORTES LOPEZ, MARIELA
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: anti-cancer immunotherapy, anticancer immunotherapy